Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
